I had exactly the same issue. Private insurance refused to pay as did not fully meet the criteria used in the Stampede study. Me, T3bNOMO, PSA=23, Gleeson 3+4=7, but needed to have PSA of 40 I believe.
Disappointing, The summary of the Lancet study says:
"In summary, men with high-risk non-matastatic prostate cancer who receive ADT with combination therapy have significantly better metatastases-free survival and overall survival than those who receive ADT alone. 2 years of abiraterone and prednisolone added to ADT and, if indicated, radiotherapy should be considered a new standard treatment for non-metastatic prostate cancer with high-risk features"
I looked into independent supply, and it's widely available from India at significantly reduced price.
https://api.drreddys.com/product/abiraterone-acetate
https://abirateroneacetatecost.com/
https://www.medixocentre.com/cancer/buy-abiraterone-bdron-online
I researched this, and it's quite legit. Its an off-patent drug. India manufactures 80% of UK's pharmaceuticals anyway. The story is political. For it to be repurposed for earlier stages and covered by the NHS prescription scheme the pharma companies have to apply to NICE. These repurposing costs are significant so the OEM has no financial motivation because they won't be able to recoup the costs as the drug is out of patent. So it remains in limbo. https://bnf.nice.org.uk/drugs/abiraterone-acetate
Another issue (with own supply) is it could negate the terms of my private insurance. So I did not proceed and am on standard treatment of ADT/RT.
Edited by member 18 Jul 2024 at 11:47
| Reason: typo